Community Trust & Investment Co. Reduces Stock Holdings in IQVIA Holdings Inc. $IQV

Community Trust & Investment Co. trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 100,312 shares of the medical research company’s stock after selling 8,599 shares during the period. IQVIA accounts for approximately 1.2% of Community Trust & Investment Co.’s portfolio, making the stock its 23rd largest holding. Community Trust & Investment Co. owned 0.06% of IQVIA worth $22,611,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in IQV. Physician Wealth Advisors Inc. lifted its position in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the last quarter. Westside Investment Management Inc. increased its holdings in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new stake in IQVIA in the 3rd quarter valued at about $30,000. Atlantic Union Bankshares Corp bought a new stake in IQVIA in the 3rd quarter valued at about $36,000. Finally, Root Financial Partners LLC bought a new position in IQVIA during the third quarter worth about $43,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $167.14 on Tuesday. The company has a 50 day moving average of $192.66 and a 200 day moving average of $206.07. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market cap of $28.36 billion, a P/E ratio of 21.27, a P/E/G ratio of 1.60 and a beta of 1.40. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same period in the prior year, the company posted $3.12 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on IQV shares. Evercore reiterated an “outperform” rating and issued a $225.00 target price on shares of IQVIA in a research note on Thursday, February 5th. JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. BMO Capital Markets set a $250.00 target price on IQVIA in a research report on Friday, February 6th. Finally, TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and raised their price target for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Buy” and an average target price of $229.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.